Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Restructuring (2016 - 2017)

Historic Cash from Restructuring for Altimmune (ALT) over the last 3 years, with Q1 2017 value amounting to -$66633.0.

  • Altimmune's Cash from Restructuring rose 6612.73% to -$66633.0 in Q1 2017 from the same period last year, while for Mar 2017 it was -$267300.0, marking a year-over-year increase of 8335.17%. This contributed to the annual value of -$397383.0 for FY2016, which is 18248.55% down from last year.
  • As of Q1 2017, Altimmune's Cash from Restructuring stood at -$66633.0, which was up 6612.73% from -$66633.0 recorded in Q4 2016.
  • In the past 5 years, Altimmune's Cash from Restructuring registered a high of $1.9 million during Q1 2015, and its lowest value of -$1.1 million during Q2 2015.
  • Its 3-year average for Cash from Restructuring is $7306.6, with a median of -$66727.0 in 2016.
  • Over the last 5 years, Altimmune's Cash from Restructuring had its largest YoY gain of 9393.39% in 2016, and its largest YoY loss of 76299.25% in 2016.
  • Quarter analysis of 3 years shows Altimmune's Cash from Restructuring stood at -$319008.0 in 2015, then soared by 79.11% to -$66633.0 in 2016, then changed by 0.0% to -$66633.0 in 2017.
  • Its Cash from Restructuring stands at -$66633.0 for Q1 2017, versus -$66633.0 for Q4 2016 and -$67307.0 for Q3 2016.